White Paper: Considerations for Developing Saliva-based Lateral Flow Immunoassays
Lateral flow assays (LFAs) designed for diagnostic applications at home (over-the-counter, OTC) and point-of-care (PoC) are simple to use and can test for a wide variety of biomarkers in a diverse set of matrices including saliva, nasal swabs, blood, and urine.
Saliva is considered a highly attractive sample matrix for LFA, due to its ease of access, non-invasive sample collection process, reduced risk of disease transmission, and the presence of a wide and diverse range of biomarkers that are readily accessible for rapid testing.
However, it comes with its own challenges because it is prone to matrix effects, varies greatly from patient to patient, and may have lower analyte concentrations than other sample types.
This white paper highlights the key considerations to ensure the successful development of saliva-based LFAs including:
By clicking “Acknowledge”, you consent to our website's use of cookies to give you the most relevant experience by remembering your preferences and to analyze our website traffic.
